Multi-cancer blood testing combined with PET-CT: road for hope to screen for cancer and guide intervention

por Jiang, Tao, Ren, Shengxiang, Zhou, Caicun
Publicado 2020

Current status and future perspectives of bispecific antibodies in the treatment of lung cancer

por Wang, Wanying, Qiu, Tianyu, Li, Fei, Ren, Shengxiang
Publicado 2023

Pan-cancer analysis of ARID1A Alterations as Biomarkers for Immunotherapy Outcomes

por Jiang, Tao, Chen, Xiaoxia, Su, Chunxia, Ren, Shengxiang, Zhou, Caicun
Publicado 2020

Differences in treatment effect size between progression-free survival and overall survival in anti-PD-1/PD-L1 inhibitors-based trials in advanced NSCLC: a systematic review and me...

por Zhou, Zhirui, Ren, Shengxiang, Chen, Lingxiao, Zhou, Caicun, Jiang, Tao
Publicado 2021

Comparison of stereotactic body radiotherapy and radiofrequency ablation for early-stage non-small cell lung cancer: a systematic review and meta-analysis

por Zhang, Ran, Kang, Jingjing, Ren, Shengxiang, Xing, Ligang, Xu, Yaping
Publicado 2022

The Association between COX-2 Polymorphisms and Hematologic Toxicity in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Platinum-Based Chemotherapy

por Zhou, Fei, Gao, Guanghui, Ren, Shengxiang, Li, Xuefei, He, Yayi, Zhou, Caicun
Publicado 2013

Prognostic value of high EZH2 expression in patients with different types of cancer: a systematic review with meta-analysis

por Jiang, Tao, Wang, Yan, Zhou, Fei, Gao, Guanghui, Ren, Shengxiang, Zhou, Caicun
Publicado 2015

Epidemiological study of HER-2 mutations among EGFR wild-type lung adenocarcinoma patients in China

por Li, Xuefei, Zhao, Chao, Su, Chunxia, Ren, Shengxiang, Chen, Xiaoxia, Zhou, Caicun
Publicado 2016

Front-line treatment for advanced non-small-cell lung cancer and ALK fusion: a network meta-analysis

por Wen, Yaokai, Jiang, Tao, Wu, Xiangrong, Peng, Haoxin, Ren, Shengxiang, Zhou, Caicun
Publicado 2022

Detecting ALK, ROS1 and RET Fusion Genes in Cell Block Samples()()

por Zhao, Chao, Li, Xuefei, Li, Jiayu, Zhang, Yishi, Ren, Shengxiang, Chen, Xiaoxia, Zhou, Caicun
Publicado 2014

Immune-checkpoint inhibitors plus chemotherapy versus chemotherapy as first-line treatment for patients with extensive-stage small cell lung cancer

por Zhou, Fei, Zhao, Wencheng, Gong, Xiaomei, Ren, Shengxiang, Su, Chunxia, Jiang, Tao, Zhou, Caicun
Publicado 2020

Role of surgery in a case-control study of patients with clinical stage IIIA small cell lung cancer

por Li, Shuangyi, Jin, Kaiqi, Pan, Yingying, Wu, Chunxiao, Ren, Shengxiang, Jiang, Gening, Zhang, Peng
Publicado 2021

Case Report: Abscopal Effect of Microwave Ablation in a Patient With Advanced Squamous NSCLC and Resistance to Immunotherapy

por Shao, Chuchu, Yang, Menghang, Pan, Yingying, Xie, Dacheng, Chen, Bin, Ren, Shengxiang, Zhou, Caicun
Publicado 2021

Association between Single Nucleotide Polymorphisms (SNPs) and Toxicity of Advanced Non-Small-Cell Lung Cancer Patients Treated with Chemotherapy

por Zhang, Ling, Gao, Guanghui, Li, Xuefei, Ren, Shengxiang, Li, Aiwu, Xu, Jianfang, Zhang, Jie, Zhou, Caicun
Publicado 2012

Immunotherapy with Dendritic Cells Modified with Tumor-Associated Antigen Gene Demonstrates Enhanced Antitumor Effect Against Lung Cancer()

por Jiang, Tao, Chen, Xiao, Zhou, Wei, Fan, Guoxin, Zhao, Peilin, Ren, Shengxiang, Zhou, Caicun, Zhang, Jun
Publicado 2017

Addition of bevacizumab for malignant pleural effusion as the manifestation of acquired EGFR-TKI resistance in NSCLC patients

por Jiang, Tao, Li, Aiwu, Su, Chunxia, Li, Xuefei, Zhao, Chao, Ren, Shengxiang, Zhou, Caicun, Zhang, Jun
Publicado 2017

Outcomes of Pemetrexed-based chemotherapies in HER2-mutant lung cancers

por Wang, Yan, Zhang, Shijia, Wu, Fengying, Zhao, Jing, Li, Xuefei, Zhao, Chao, Ren, Shengxiang, Zhou, Caicun
Publicado 2018

First-line continual EGFR-TKI plus local ablative therapy demonstrated survival benefit in EGFR-mutant NSCLC patients with oligoprogressive disease

por Xu, Qinghua, Liu, Hui, Meng, Shuyan, Jiang, Tao, Li, Xuefei, Liang, Shixiong, Ren, Shengxiang, Zhou, Caicun
Publicado 2019

Clinical features and therapeutic options in non‐small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF

por Zhuang, Xibin, Zhao, Chao, Li, Jiayu, Su, Chunxia, Chen, Xiaoxia, Ren, Shengxiang, Li, Xuefei, Zhou, Caicun
Publicado 2019

Tumor neoantigens: from basic research to clinical applications

por Jiang, Tao, Shi, Tao, Zhang, Henghui, Hu, Jie, Song, Yuanlin, Wei, Jia, Ren, Shengxiang, Zhou, Caicun
Publicado 2019